Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.

Conclusions: These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma. PMID: 30429708 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30429708?dopt=Abstract

Source: Advances in Dermatology and Allergology - November 17, 2018 Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research

More News: Asthma | Dermatology | Skin | Study | Xolair